heart failure and preserved ejection fraction

AstraZeneca’s Farxiga confident of its edge over Novo’s Wegovy in heart failure market

Novo Nordisk’s semaglutide and AstraZeneca’s Farxiga assuming the roles of formidable contenders. The arena is no longer confined to blood ...